Pe-22-28

Pe-22-28 Cognitive & Nootropic Overview

Pe-22-28 is a meticulously engineered neurotrophic compound for synaptic growth, neuronal protection, and optimized cerebral signaling.

Physiochemical Profile

Parameter	Value
Formula	C130H205N39O41S
Mass	2914.3 g/mol
Purity	>98.0%
Appearance	White lyophilized powder

Figure 1: Pe-22-28 Neurological Pathway

Cerebral Mechanism of Action

1. Functions as a highly potent modulator of the TREK-1 potassium channel.
2. TREK-1 channels are implicated as the primary downstream target of SSRI antidepressants.
3. Blocks TREK-1 conductance forcing increased serotonergic and noradrenergic signaling.
4. Produces rapid-onset antidepressant-like effects within hours instead of weeks.
5. Simultaneously provides potent neuroprotection against excitotoxic glutamate damage.

Figure 2: Synaptogenesis Rate

Research Outcomes

• 1: Considered a next-generation non-SSRI antidepressant mechanism.
• 2: Achieves mood normalization far more rapidly than conventional serotonin reuptake inhibitors.
• 3: Demonstrates significant cognitive enhancement as a secondary effect.

Spadin Analogue: TREK-1 Channel Antagonism

Pe-22-28 is a synthetic heptapeptide derived from the sortilin propeptide (PE), specifically residues 22–28. It functions as a potent antagonist of the TREK-1 (TWIK-Related K+ Channel 1) potassium channel, a two-pore-domain background potassium channel abundantly expressed in hippocampal and cortical neurons. TREK-1 channel blockade represents one of the most promising novel antidepressant targets: TREK-1 knockout mice display a phenotype remarkably resistant to depression and anxiety, mimicking chronic antidepressant treatment without the 2–4 week therapeutic lag of SSRIs.

1. Pe-22-28 blocks TREK-1 channels by binding the extracellular cap domain, preventing potassium efflux and increasing neuronal excitability in serotonergic and glutamatergic neurons.
2. In dorsal raphe serotonergic neurons, TREK-1 blockade increases firing rate and 5-HT release within hours, bypassing the autoreceptor desensitization delay required by SSRIs.
3. Hippocampal BDNF expression increases within 24 hours of TREK-1 antagonism, compared to 2–3 weeks with conventional antidepressants.
4. Hippocampal neurogenesis in the subgranular zone is stimulated by 4 days of TREK-1 blockade, a timeframe dramatically faster than any current antidepressant class.
5. The compound also enhances hippocampal LTP, directly linking its antidepressant mechanism to cognitive enhancement and memory consolidation.

Antidepressant & Nootropic Research

• Rapid Onset: In forced swim and tail suspension tests, Pe-22-28 produces antidepressant-like behavioral effects within 4 days, compared to 14–21 days for fluoxetine.
• vs. Spadin: Pe-22-28 is a truncated, optimized version of the 17-amino acid spadin peptide, offering improved synthesis efficiency and comparable TREK-1 antagonism.
• Dual Benefit: The rapid BDNF induction and neurogenesis stimulation provide both antidepressant and pro-cognitive effects, positioning Pe-22-28 as a cognitive-enhancing anxiolytic.
• Safety: TREK-1 antagonism does not affect cardiac TREK channels at therapeutic concentrations, as neuronal TREK-1 has distinct pharmacological sensitivity.
• Administration: Intraperitoneal or intranasal administration in research models. The small size (7 amino acids) provides favorable tissue penetration. Store lyophilized at −20°C.